Teva Counts Its NYSE Direct Listing Among Q3 Milestones
Teva's Q3 release lists the NYSE direct listing of its ordinary shares beside an investment-grade return and $4.9 billion of refinancing. What it signals.
When a large foreign issuer changes the way its stock trades in New York, the change rarely arrives as a stand-alone announcement. It tends to surface in the paragraphs a company uses to explain why management is pleased with the year. Teva Pharmaceutical Industries did exactly that on Nov. 3, when its third-quarter earnings release, furnished to the SEC on Form 8-K, placed the NYSE direct listing of its ordinary shares in a short list of financial achievements.
A listing change filed under earnings
The release, dated Tel Aviv and issued the same day, describes Teva as trading on the NYSE and the Tel Aviv Stock Exchange under the symbol TEVA. In a highlights bullet on “financial strength,” the company groups three items: its return to an investment-grade credit rating, the refinancing of about $4.9 billion of debt during the quarter, and “the direct listing of Teva’s ordinary shares on the New York Stock Exchange.” Management presents all three as evidence that its “Pivot to Growth” strategy is working.
The forward-looking statements add detail on the mechanics. They refer to the process for terminating Teva’s American depositary share program and directly listing ordinary shares “in lieu of the ADSs,” a step the company calls the “Conversion.” Teva points readers to Part II, Item 5 of its quarterly report on Form 10-Q and to its investor relations site for the full description, and it lists the company’s ability to carry out the Conversion and achieve its aims among the factors that could cause results to differ.
That wording matters for readers tracking exchange-listing structures. An NYSE direct listing of existing ordinary shares in place of an ADS program is a change in the form of the security, not a capital raise. No offering is priced and no underwriter allocates stock. What changes is how foreign-issuer shares are held, settled and quoted by U.S. investors.
The numbers that frame the decision
The quarter itself was mixed on the top line and strong on margins. Revenue was $4.4 billion, down 2% from a year earlier, which Teva attributed mainly to generic lenalidomide competition in the United States. Gross profit margin reached 55.5%, against 51.4% a year earlier, and non-GAAP diluted earnings per share were $0.86. Free cash flow was about $0.5 billion.
On the balance sheet, the release says Moody’s and S&P upgraded Teva to investment grade during the third quarter, following an earlier upgrade by Fitch, and that the debt refinancing supports a goal of two times debt leverage by the end of 2027. The filing’s financial-leverage measure, the ratio of debt to debt plus equity, stood at 68% on Sept. 30, 2026, unchanged from Dec. 31, 2025, and average debt maturity was about 6.3 years.
A company that has just regained investment-grade ratings and termed out its debt is in a strong position to ask for a simpler share structure.
That sequencing is our reading rather than anything Teva states in so many words. The release simply places the listing change alongside the credit upgrades and refinancing as parts of one story.
What it means for other issuers
Many direct listings involve smaller companies moving from the OTC markets to a national exchange, or private companies listing without an offering. Teva is a different case: an established, NYSE-traded issuer with a dual listing in Tel Aviv that is reorganizing how its U.S. shares exist.
For foreign private issuers weighing their own U.S. presence, the filing is a data point on how a large cross-border company describes the trade-off. Teva frames the change as a benefit to shareholders and ties it to the strength of its finances, while also acknowledging execution risk in the Conversion.
What to watch
Readers should look to the Form 10-Q’s Item 5 discussion for the specific steps and timing of the ADS termination, and to later Teva filings for confirmation of how the ordinary shares trade after the change. Whether other large issuers with ADS programs follow with their own direct listings will depend largely on how smoothly this one settles.
Prepared with AI assistance from public sources and reviewed under our editorial policy. Not investment advice.

